Top Page
Elixinol Wellness
(Sydney:EXL)
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Elixinol Wellness Business Overview & Revenue Model
Elixinol Wellness Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.85M | 14.96M | 8.27M | 7.05M | 9.34M | 15.01M |
| Gross Profit | 5.59M | 5.36M | -1.80M | -3.27M | -6.25M | -9.58M |
| EBITDA | -5.00M | -4.06M | -6.81M | -9.28M | -15.51M | -95.94M |
| Net Income | -2.06M | -1.72M | -7.51M | -10.57M | -17.02M | -104.51M |
Balance Sheet | ||||||
| Total Assets | 16.58M | 18.45M | 11.71M | 13.48M | 25.33M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 1.08M | 708.00K | 2.86M | 12.65M | 27.74M |
| Total Debt | 3.10M | 1.94M | 1.26M | 1.83M | 2.71M | 2.74M |
| Total Liabilities | 9.61M | 8.42M | 5.25M | 4.33M | 6.25M | 6.82M |
| Stockholders Equity | 6.96M | 10.03M | 6.46M | 9.16M | 19.08M | 35.65M |
Cash Flow | ||||||
| Free Cash Flow | -2.73M | -3.53M | -2.77M | -8.16M | -14.36M | -22.95M |
| Operating Cash Flow | -2.71M | -3.47M | -2.76M | -8.15M | -14.07M | -22.62M |
| Investing Cash Flow | -516.00K | -66.00K | -1.04M | -869.00K | 172.00K | 2.55M |
| Financing Cash Flow | 2.76M | 3.92M | 1.61M | -757.00K | -1.16M | 27.55M |
Elixinol Wellness Technical Analysis
Elixinol Wellness Peers Comparison
Elixinol Wellness Corporate Events
Elixinol Wellness Ltd has postponed its Extraordinary General Meeting originally scheduled for 31 October 2025 to 11 November 2025 due to an administrative error by the share registrar, which failed to notify certain shareholders within the statutory timeframes. The company is committed to ensuring all shareholders have a fair opportunity to participate and vote, and will issue a new Notice of Meeting and related documents. This postponement underscores Elixinol’s dedication to transparency and shareholder engagement, despite the inconvenience caused.
Elixinol Wellness Limited announced the cancellation of a previous securities issuance announcement due to the expiration of the offer period associated with a cleansing prospectus. This decision reflects the company’s adherence to regulatory requirements and impacts its operational plans regarding the proposed non-pro rata offer of securities.
Elixinol Wellness Limited has announced an Extraordinary General Meeting to be held virtually on October 31, 2025. This meeting will allow shareholders to discuss and vote on company matters, with proxy voting available online. The company emphasizes its commitment to environmental sustainability by offering digital access to meeting documents.
Elixinol Wellness Limited announced an update to a previous securities issue announcement, detailing the issuance of 35 million options to the lead manager as part of a fee arrangement. This issuance is contingent upon shareholder approval and a minimum placement raising of AUD1.5 million, with the options exercisable at 2 cents and expiring on October 23, 2027. This move aims to enhance the company’s financial strategy and potentially strengthen its market position.
Elixinol Wellness Limited, listed on the ASX under the code EXL, has announced a prospectus for an offer of up to 100,000 new shares at $0.10 each, aiming to raise up to $10,000. The prospectus is designed to remove trading restrictions on the sale of shares issued under this offer and previous ones. The company emphasizes that the investment should be considered speculative, with no guarantees on returns or dividends, and advises potential investors to seek professional advice.
Elixinol Wellness Limited has announced the quotation of 46,800,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 12, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing stakeholders with increased liquidity and investment opportunities.
Elixinol Wellness Limited announced a proposed issue of securities, including options and ordinary fully paid shares, set to be issued on October 24, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market position and providing opportunities for stakeholders to engage with its growth initiatives.
Elixinol Wellness Limited has announced a proposed issue of 46,800,000 ordinary fully paid securities, with the issue date set for September 12, 2025. This move is part of the company’s strategic efforts to enhance its market position and potentially raise capital for future growth initiatives, impacting its operational capabilities and stakeholder interests.
Elixinol Wellness Ltd has successfully raised $2.5 million through a well-supported two-tranche placement, exceeding its initial target of $2 million. The funds will be used to enhance working capital, support inventory growth, streamline operations, and shift towards higher-margin channels to achieve sustained profitability. The company has also appointed Gavin Evans as a strategic advisor to aid in its transformation, following recent acquisitions. This move reflects strong investor confidence in Elixinol’s brands and strategic direction, positioning the company for profitable growth.
Elixinol Wellness Limited has requested a trading halt on its securities pending an announcement regarding a potential financing or capital raising arrangement. This halt is expected to last until the announcement is made or until normal trading resumes on 8 September 2025, indicating a significant upcoming development that could impact the company’s financial strategy and market position.
Elixinol Wellness Limited has released its H1 2025 results presentation, which provides a general overview of the company’s current status and future business intentions. The presentation includes forward-looking statements that highlight potential risks and uncertainties, emphasizing the need for investors to exercise caution and not rely solely on the provided information.
Elixinol Wellness Limited reported a 12.8% year-on-year revenue growth to $7.6 million for the first half of 2025, driven by strong performances from Healthy Chef and Hemp Foods Australia. Despite a loss in adjusted EBITDA due to integration costs, the company achieved margin expansion and improved cash discipline, positioning itself for a stronger second half of the year. The focus remains on e-commerce growth and cost rationalization to sustain momentum into 2026.
Elixinol Wellness Limited reported a 12.8% increase in revenues to $7,642,000 for the half-year ending June 30, 2025, despite a 12.2% increase in losses, totaling $3,093,000. The company’s financial performance reflects ongoing challenges, with no dividends declared and a decrease in net tangible assets, highlighting the need for strategic adjustments to improve profitability and shareholder value.
Elixinol Wellness Ltd has decided to terminate a U.S. distribution agreement for The Healthy Chef products, which was assumed during its acquisition of the brand in 2024. This move allows Elixinol to concentrate on expanding The Healthy Chef’s presence in the Australian market while maintaining the option to explore international opportunities in the future.
Elixinol Wellness reported a rebound in revenue and customer receipts in Q2 2025, with a 10.8% year-over-year increase in revenue to $4.1 million. The company is implementing aggressive cost control measures and has secured funding to support its push to profitability. The brand portfolio showed mixed results, with some brands experiencing growth and others undergoing consolidation. Product innovation continues with new launches planned in the well-ageing category and other functional products.